Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/8283
Title: Costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections
Authors: Karahasanoğlu, Fatma Banu
Asan, A.
Saçar, Suzan
Turgut, Hüseyin
Keywords: Chronic hepatitis B
Chronic hepatitis C
Cost
adefovir
entecavir
lamivudine
peginterferon alpha2a
peginterferon alpha2b
ribavirin
tenofovir
adolescent
adult
aged
antiviral therapy
article
cost of illness
cross-sectional study
drug cost
drug substitution
drug withdrawal
echography
female
follow up
hepatitis B
hepatitis C
hospital cost
human
human tissue
liver biopsy
liver cirrhosis
major clinical study
male
osteoporosis
questionnaire
Turkey (republic)
virus carrier
Publisher: Galenos Publishing House
Abstract: Background: Few studies have addressed the indirect costs of chronic hepatitis B and C, and none has assessed the real costs of these conditions, including indirect costs caused by loss of work, in Turkey. Aims: This study therefore analysed the costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections to the community. Study design: Cross-sectional study. Methods: This study analysed patients with chronic hepatitis B and hepatitis C treated at Pamukkale University Hospital Infectious Diseases and Clinical Microbiology Clinic, Denizli, Turkey between June 2009 and June 2010. Costs of antiviral treatment and follow-up were calculated from patients' medical records, and indirect costs were analysed from questionnaires completed by patients. Results: Data were analysed for 284 patients with chronic viral hepatitis. Indirect, hospital, treatment and total expenses were significantly higher for patients with chronic hepatitis B than for inactive hepatitis B virus carriers and patients with chronic hepatitis C. Hospital and total expenses of patients with complications were significantly higher than for patients with chronic hepatitis C. Hospital and total expenses were significantly higher for patients with than for individuals without cirrhosis. Indirect, hospital, treatment and total costs of patients were significantly higher for patients receiving combination therapy than monotherapy. Conclusion: Reducing the costs to society of chronic hepatitis requires the development of protection and screening programs. © Trakya University Faculty of Medicine.
URI: https://hdl.handle.net/11499/8283
https://doi.org/10.5152/balkanmedj.2013.7547
ISSN: 2146-3123
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
10.5152 balkanmedj.2013.7547.pdf128.67 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

7
checked on Sep 30, 2024

WEB OF SCIENCETM
Citations

6
checked on Sep 30, 2024

Page view(s)

50
checked on Aug 24, 2024

Download(s)

18
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.